| 62.19 -0.8 (-1.27%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 82.24 | 1-year : | 96.06 |
| Resists | First : | 70.41 | Second : | 82.24 |
| Pivot price | 64.17  |
|||
| Supports | First : | 58.3 | Second : | 50.81 |
| MAs | MA(5) : | 62.53 |
MA(20) : | 62.32 |
| MA(100) : | 59.21 |
MA(250) : | 67.17 |
|
| MACD | MACD : | 1.6 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 36 |
D(3) : | 41.9 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 85.83 | Low : | 50.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDNT ] has closed above bottom band by 32.7%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.19 - 63.54 | 63.54 - 63.83 |
| Low: | 57.93 - 58.41 | 58.41 - 58.79 |
| Close: | 61.46 - 62.2 | 62.2 - 62.8 |
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
Tue, 07 Jul 2026
RadNet (RDNT) Launches Reporting Pro, Is The Stock Still Undervalued? - Sahm
Tue, 07 Jul 2026
How RadNet’s (RDNT) AI Reporting Tools Could Improve Imaging Center Scale and Workflow - Yahoo Finance
Mon, 22 Jun 2026
RadNet Inc (RDNT) Stock Up 3.8% and Still Undervalued -- GF Scor - GuruFocus
Wed, 17 Jun 2026
Why RadNet (RDNT) Stock Is Down Today - Yahoo Finance
Fri, 29 May 2026
Barclays Lowers RadNet (RDNT) Price Target, Says Imaging Business Continues to Outperform - Yahoo Finance
Thu, 14 May 2026
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 79 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 100.5 (%) |
| Shares Short | 10,000 (K) |
| Shares Short P.Month | 9,170 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.07 |
| Profit Margin | -0.7 % |
| Operating Margin | -2.9 % |
| Return on Assets (ttm) | 1.5 % |
| Return on Equity (ttm) | 1.7 % |
| Qtrly Rev. Growth | 22.1 % |
| Gross Profit (p.s.) | 4.69 |
| Sales Per Share | 27.21 |
| EBITDA (p.s.) | 3.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 336 (M) |
| Levered Free Cash Flow | 190 (M) |
| PE Ratio | -365.83 |
| PEG Ratio | 0.9 |
| Price to Book value | 4.41 |
| Price to Sales | 2.28 |
| Price to Cash Flow | 14.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|